113 related articles for article (PubMed ID: 20022474)
1. Evaluation of azithromycin, trovafloxacin and grepafloxacin as prophylaxis against experimental murine Brucella melitensis infection.
Atkins HS; Spencer S; Brew SD; Jenner DC; Sefton AM; MacMillan AP; Brooks TJ; Simpson AJ
Int J Antimicrob Agents; 2010 Jul; 36(1):66-8. PubMed ID: 20022474
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of azithromycin, trovafloxacin and grepafloxacin as prophylaxis for experimental murine melioidosis.
Kenny DJ; Sefton AM; Brooks TJ; Laws TR; Simpson AJ; Atkins HS
Int J Antimicrob Agents; 2010 Jul; 36(1):87-9. PubMed ID: 20462743
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of moxifloxacin or gatifloxacin as prophylaxis against experimental murine Brucella melitensis infection.
Atkins HS; Spencer S; Brew SD; Laws TR; Thirlwall RE; MacMillan AP; Brooks TJ; Simpson AJ
Int J Antimicrob Agents; 2009 Nov; 34(5):471-3. PubMed ID: 19682862
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of ciprofloxacin versus doxycycline as prophylaxis against experimental murine Brucella melitensis infection.
Atkins HS; Spencer S; Brew SD; Jenner DC; Russell P; MacMillan AP; Eley SM; Simpson AJ
Int J Antimicrob Agents; 2009 Nov; 34(5):474-6. PubMed ID: 19500948
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of the quinolones trovafloxacin and grepafloxacin for therapy of experimental tularaemia and plague.
Kenny DJ; Sefton AM; Steward J; Brooks TJ; Simpson AJ; Atkins HS
Int J Antimicrob Agents; 2009 Nov; 34(5):502-3. PubMed ID: 19699615
[No Abstract] [Full Text] [Related]
6. Inadequate azithromycin activity against Brucella melitensis in mice with acute or chronic infections.
Domingo S; Gamazo C
J Chemother; 1996 Feb; 8(1):55-8. PubMed ID: 8835110
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of several antibiotic combinations against Brucella melitensis Rev 1 experimental infection in BALB/c mice.
Grilló MJ; De Miguel MJ; Muñoz PM; Marín CM; Ariza J; Blasco JM
J Antimicrob Chemother; 2006 Sep; 58(3):622-6. PubMed ID: 16849379
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of Brucella melitensis B115 as rough-phenotype vaccine against B. melitensis and B. ovis infections.
Adone R; Francia M; Ciuchini F
Vaccine; 2008 Sep; 26(38):4913-7. PubMed ID: 18675869
[TBL] [Abstract][Full Text] [Related]
9. Comparative activity of azithromycin and doxycycline against Brucella spp. infection in mice.
Domingo S; Gastearena I; Vitas AI; López-Goñi I; Dios-Viéitez C; Díaz R; Gamazo C
J Antimicrob Chemother; 1995 Oct; 36(4):647-56. PubMed ID: 8591939
[TBL] [Abstract][Full Text] [Related]
10. Development and evaluation as vaccines in mice of Brucella melitensis Rev.1 single and double deletion mutants of the bp26 and omp31 genes coding for antigens of diagnostic significance in ovine brucellosis.
Cloeckaert A; Jacques I; Grilló MJ; Marín CM; Grayon M; Blasco JM; Verger JM
Vaccine; 2004 Jul; 22(21-22):2827-35. PubMed ID: 15246618
[TBL] [Abstract][Full Text] [Related]
11. In vitro activities of six new fluoroquinolones against Brucella melitensis.
Trujillano-Martín I; García-Sánchez E; Martínez IM; Fresnadillo MJ; García-Sánchez JE; García-Rodríguez JA
Antimicrob Agents Chemother; 1999 Jan; 43(1):194-5. PubMed ID: 9869594
[TBL] [Abstract][Full Text] [Related]
12. Prevention of laboratory-acquired brucellosis: significant side effects of prophylaxis.
Maley MW; Kociuba K; Chan RC
Clin Infect Dis; 2006 Feb; 42(3):433-4. PubMed ID: 16392095
[No Abstract] [Full Text] [Related]
13. Oral vaccination with Brucella melitensis WR201 protects mice against intranasal challenge with virulent Brucella melitensis 16M.
Izadjoo MJ; Bhattacharjee AK; Paranavitana CM; Hadfield TL; Hoover DL
Infect Immun; 2004 Jul; 72(7):4031-9. PubMed ID: 15213148
[TBL] [Abstract][Full Text] [Related]
14. Protection of BALB/c mice against homologous and heterologous species of Brucella by rough strain vaccines derived from Brucella melitensis and Brucella suis biovar 4.
Winter AJ; Schurig GG; Boyle SM; Sriranganathan N; Bevins JS; Enright FM; Elzer PH; Kopec JD
Am J Vet Res; 1996 May; 57(5):677-83. PubMed ID: 8723881
[TBL] [Abstract][Full Text] [Related]
15. In vitro activity of Brucella melitensis isolates to various antimicrobials in Turkey.
Denk A; Demirdag K; Kalkan A; Ozden M; Cetinkaya B; Kilic SS
Infect Dis (Lond); 2015 Jun; 47(6):364-9. PubMed ID: 25712728
[TBL] [Abstract][Full Text] [Related]
16. The identification of two protective DNA vaccines from a panel of five plasmid constructs encoding Brucella melitensis 16M genes.
Commander NJ; Spencer SA; Wren BW; MacMillan AP
Vaccine; 2007 Jan; 25(1):43-54. PubMed ID: 17049676
[TBL] [Abstract][Full Text] [Related]
17. Nasal immunization with recombinant Brucella melitensis bp26 and trigger factor with cholera toxin reduces B. melitensis colonization.
Yang X; Walters N; Robison A; Trunkle T; Pascual DW
Vaccine; 2007 Mar; 25(12):2261-8. PubMed ID: 17239499
[TBL] [Abstract][Full Text] [Related]
18. Immunological responses and protective efficacy against Brucella melitensis induced by bp26 and omp31 B. melitensis Rev.1 deletion mutants in sheep.
Jacques I; Verger JM; Laroucau K; Grayon M; Vizcaino N; Peix A; Cortade F; Carreras F; Guilloteau LA
Vaccine; 2007 Jan; 25(5):794-805. PubMed ID: 17070627
[TBL] [Abstract][Full Text] [Related]
19. Protection of BALB/c mice against Brucella melitensis 16 M infection induced by vaccination with live Escherchia coli expression Brucella P39 protein.
Al-Mariri A
Vaccine; 2010 Feb; 28(7):1766-70. PubMed ID: 20036752
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic effects of roxithromycin and azithromycin in experimental murine brucellosis.
Lang R; Shasha B; Ifrach N; Tinman S; Rubinstein E
Chemotherapy; 1994; 40(4):252-5. PubMed ID: 8082413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
